<DOC>
	<DOCNO>NCT01340885</DOCNO>
	<brief_summary>The purpose study determine relationship attention quality life rivastigmine atomoxetine alter attention non-demented person Parkinson 's disease ( PD ) .</brief_summary>
	<brief_title>Cognitive Decline Non-demented PD</brief_title>
	<detailed_description>Cognitive dysfunction occur early stage Parkinson 's disease ( PD ) increase PD progress . Attention deficit PD patient dementia strongly predict impairment daily living activity . Previous study show atomoxetine improves PD executive dysfunction rivastigmine improve attention deficit PD patient dementia without worsen motor symptom . The aim study examine effect atomoxetine rivastigmine attention quality life PD patient without disable cognitive impairment .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Clinical diagnosis Parkinson 's disease Respond levodopa therapy Dementia Psychiatric disorder include anxiety disorder , dissociative disorder , mood disorder , schizophrenia related disorder , ADD/ADHD Any clinically unstable disease cancer , HIV/AIDS , heart condition , liver disease , kidney renal failure others might require hospitalization Evidence another neurological disease ( history seizure , Alzheimer disease , multiple sclerosis movement disorder ) ; Currently use study drug ; Colorblindness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>attention</keyword>
	<keyword>mild cognitive impairment</keyword>
	<keyword>dementia</keyword>
</DOC>